Cardiovascular disease risk in early rheumatoid arthritis: the impact of cartilage oligomeric matrix protein (COMP) and disease activity

Table 2 Treatment and disease parameters at inclusion and at 2 years

	Inclusion (n = 232)	2 years (n = 207) ^a
Current treatment
DMARD (any), n (%)	190 (82)	171 (83)
MTX, n (%)	123 (53)	125 (60)
MTX dose (mg/week)	10 (7.5–10.0)	10 (7.5–17.5)
Other DMARDS, n (%)	67 (29)	43 (21)
Concurrent prednisolone, n (%)	89 (38)	62 (30)
Prednisolone dose (mg/day)	7.5 (5.0–15.0)	5 (2.5-6.0)
Disease parameters
RF-positive at inclusion, n (%)	143 (62)	N/A
Anti-CCP antibody-positive at inclusion, n (%)	115 (57)	N/A
Erosions present ^b, n (%)	35 (15)	67 (32)
COMP (units/L)	11 (9–14)	N/R
DAS28	4.7 (3.6–5.7)	3.5 (2.6–4.5)
Low disease activity ^c, n (%)	39 (17)	85 (41)
Moderate disease activity ^c, n (%)	103 (45)	93 (45)
High disease activity ^c, n (%)	89 (39)	27 (13)
HAQ	0.75 (0.38–1.25)	0.50 (0.00–1.00)
ESR (mm/h)	21 (10–43)	15 (8–26)
CRP (mg/l)	9 (< 9–28)	< 9 (< 9–11)

Median (IQR) given unless otherwise stated
DMARD, disease-modifying antirheumatic drugs; MTX, methotrexate; RF, rheumatoid factor; N/A, not applicable; Anti-CCP, anti-cyclic citrullinated peptide antibodies; COMP, cartilage oligomeric matrix protein; N/R, not reported; DAS28, disease activity score in 28 joints; HAQ, health assessment questionnaire; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; IQR, inter quartile range
For treatment and disease parameters at inclusion/two years, missing numbers were as follows: Anti-CCP = 31/-, Erosion present = 0/7, COMP = 30/-, DAS28 = 1/2, HAQ = 1/0, ESR = 0/2.
^a Patients with a clinical follow-up at 2 years
^b Determined by a radiologist as part of standard clinical practice
^c DAS28-classifications: Low ≤ 3.2; Moderate > 3.2-≤5.1; High > 5.1

ISSN: 2520-1026